ReviewHypertension (Dallas, Tex. : 1979)2017
Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition.
Open access · bronzeAbstract readReview
In one paragraph
Review in Hypertension (Dallas, Tex. : 1979), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 2 pooled it
6.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Pooled safety profiles of bispecific antibodies targeting PD-1/CTLA-4 or PD-1/VEGF in non-small cell lung cancer: a systematic review and single-arm meta-analysis.Journal of the Egyptian National Cancer Institute · 2026Pooled it
- Efficacy and safety of anlotinib combined with immune checkpoint inhibitors in the treatment of extensive-stage small cell lung cancer: a meta-analysis based on real-world data.BMC pulmonary medicine · 2025Pooled it
- Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation.Journal of hypertension · 2020Trial
- Automated optical coherence tomography quantification of retinal wall-to-lumen alterations in preeclampsia.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Relationships of serum cabozantinib concentration with tumor response and adverse events in treatment of advanced renal cell carcinoma: observational exploratory prospective study.International journal of clinical oncology · 2026Observational
- The gut-heart axis in cardio-oncology.Cardiovascular research · 2026Review
- Cardio-Oncology in Cold Climates: Epidemiological Features, Bidirectional Interaction Mechanisms, and Integrated Management Strategies.Cardiovascular toxicology · 2026Review
- Late-Onset Hypertension Is Associated With Improved Clinical Outcomes in Cancer Patients Treated With Sunitinib.Circulation reports · 2026Article
- Ocular pharmacokinetics of tivozanib eye drops in patients with neovascular age-related macular degeneration: comparison with phase 1 trials of oral tivozanib in solid tumors.International journal of retina and vitreous · 2026Article
- Charting the Current Landscape and Future Prospects of Cancer Therapy-Related Cardiovascular Toxicity in Cancer Survivors: From Bench to Bedside.Drug design, development and therapy · 2026Review
- Long non-coding RNAs and VEGF in ovarian cancer: mechanisms and therapeutic potential.Journal of ovarian research · 2025Review
- Cardiovascular Safety of VIAN-c4551, an Antiangiogenic Peptide Derived From Vasoinhibin.Drug development research · 2025Article
- Advances in Molecular Imaging of VEGFRs: Innovations in Imaging and Therapeutics.International journal of molecular sciences · 2025Review
- Morphometric and Molecular Interplay in Hypertension-Induced Cardiac Remodeling with an Emphasis on the Potential Therapeutic Implications.International journal of molecular sciences · 2025Review
- From Bench to Bedside: Translational Approaches to Cardiotoxicity in Breast Cancer, Lung Cancer, and Lymphoma Therapies.Cancers · 2025Review
- Changes in Serum Inflammatory Markers and in Clinical Periodontal Condition After Non-Surgical Periodontal Treatment in Hypertensive Patients.Biomedicines · 2025Article
- Acute Type A Aortic Dissection During Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor Lenvatinib Therapy.Case reports in critical care · 2025Article
- Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies.Archives of toxicology · 2025Review
- Anlotinib-induced renovascular hypertension and severe coronary artery stenosis: a case report and literature review.Frontiers in oncology · 2025Article
- Hypertensive Heart Disease: A Narrative Review Series-Part 3: Vasculature, Biomarkers and the Matrix of Hypertensive Heart Disease.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Rhian M TouyzFrom the British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.M.T., N.N.L.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (J.H.); and Division of Pharmacology and Cardiovascular Medicine, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands (A.H.v.d.M., A.H.J.D.). Rhian.Touyz@glasgow.ac.uk.
Ninian N LangFrom the British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.M.T., N.N.L.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (J.H.); and Division of Pharmacology and Cardiovascular Medicine, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands (A.H.v.d.M., A.H.J.D.).
Joerg HerrmannFrom the British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.M.T., N.N.L.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (J.H.); and Division of Pharmacology and Cardiovascular Medicine, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands (A.H.v.d.M., A.H.J.D.).
Anton H van den MeirackerFrom the British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.M.T., N.N.L.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (J.H.); and Division of Pharmacology and Cardiovascular Medicine, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands (A.H.v.d.M., A.H.J.D.).
A H Jan DanserFrom the British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United Kingdom (R.M.T., N.N.L.); Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (J.H.); and Division of Pharmacology and Cardiovascular Medicine, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands (A.H.v.d.M., A.H.J.D.).
Mayo Clinic in Arizona · US
Funding
The pathophysiological role of the immunoproteasome in atherosclerosisK08HL116952 · NHLBI · MAYO CLINIC ROCHESTER · PI HERRMANN, JOERG · 2014 to 2018
$750kBritish Heart Foundation RE/13/530177British Heart Foundation RG/13/7/30099Chief Scientist Office TCS/16/31NHLBI NIH HHS K08 HL116952
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antihypertensive AgentsHumansHypertensionReceptors, Vascular Endothelial Growth FactorSignal TransductionVascular Endothelial Growth Factor AAntihypertensive AgentsReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor A
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.